Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE

Affiliations

• ¹ McGill University Health Centre, Montreal, Québec, Canada.
• ² University of Manitoba, Winnipeg, Manitoba, Canada.
• ³ Sunnybrook Research Institute, Toronto, Ontario, Canada.
• ⁴ Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
• ⁵ New Arch Consulting, Seattle, Washington, USA.
• ⁶ Janssen, Inc., Toronto, Ontario, Canada.
• ⁷ Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
• ⁸ The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
• ⁹ Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
• ¹⁰ Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
• ¹¹ Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
• ¹² Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
• ¹³ Centre for Nephrology, University College London, London, UK.